Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

343 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparison of proportions and prognostic impact of pathological complete response between evaluations of representative specimen and total specimen in primary breast cancer after neoadjuvant chemoradiotherapy: an ancillary study of JCOG0306.
Shien T, Tsuda H, Sasaki K, Mizusawa J, Akiyama F, Kurosumi M, Sawaki M, Tamura N, Tanaka K, Kogawa T, Takahashi M, Hayashi N, Mukai H, Masuda N, Hara F, Iwata H. Shien T, et al. Among authors: akiyama f. Breast Cancer Res Treat. 2024 Nov;208(1):145-154. doi: 10.1007/s10549-024-07408-5. Epub 2024 Jun 27. Breast Cancer Res Treat. 2024. PMID: 38935214 Free PMC article. Clinical Trial.
Correction to: Validation of a nuclear grading system for resected stage I-IIIA, high-risk, node-negative invasive breast carcinoma in the N·SAS-BC 01 trial.
Tsuda H, Kurosumi M, Akiyama F, Ohno S, Saji S, Masuda N, Shimomura A, Sato N, Takao S, Ohsumi S, Tokuda Y, Inaji H, Watanabe T. Tsuda H, et al. Among authors: akiyama f. Breast Cancer. 2022 Jul;29(4):730. doi: 10.1007/s12282-022-01367-9. Breast Cancer. 2022. PMID: 35499664 Free PMC article. No abstract available.
Validation of a nuclear grading system for resected stage I-IIIA, high-risk, node-negative invasive breast carcinoma in the N·SAS-BC 01 trial.
Tsuda H, Kurosumi M, Akiyama F, Ohno S, Saji S, Masuda N, Shimomura A, Sato N, Takao S, Ohsumi S, Tokuda Y, Inaji H, Watanabe T. Tsuda H, et al. Among authors: akiyama f. Breast Cancer. 2022 Jul;29(4):720-729. doi: 10.1007/s12282-022-01350-4. Epub 2022 Apr 18. Breast Cancer. 2022. PMID: 35435571 Free PMC article.
A prediction model for early systemic recurrence in breast cancer using a molecular diagnostic analysis of sentinel lymph nodes: A large-scale, multicenter cohort study.
Osako T, Matsuura M, Yotsumoto D, Takayama S, Kaneko K, Takahashi M, Shimazu K, Yoshidome K, Kuraoka K, Itakura M, Tani M, Ishikawa T, Ohi Y, Kinoshita T, Sato N, Tsujimoto M, Nakamura S, Tsuda H, Noguchi S, Akiyama F. Osako T, et al. Among authors: akiyama f. Cancer. 2022 May 15;128(10):1913-1920. doi: 10.1002/cncr.34144. Epub 2022 Feb 28. Cancer. 2022. PMID: 35226357 Free PMC article. Clinical Trial.
343 results